Managing dyslipidaemia in the context of diabetes

Mike Kirby

People with diabetes have an increased risk of cardiovascular complications, including acute coronary syndrome, stroke, heart failure and arrhythmias. The background to this risk for the development of cardiovascular complications is multifactorial and our understanding of the nature of atherosclerotic disease has progressed considerably. This article explores the latest thinking on the link between the various facets of dyslipidaemia and cardiovascular risk and reviews current evidence for lipid management in people with diabetes.

People with diabetes have an increased risk of cardiovascular complications, including acute coronary syndrome, stroke, heart failure and arrhythmias. Data suggest that people with diabetes, without prior cardiovascular disease, have the same rate of myocardial infarction as people without diabetes who have had previous events (Haffner et al, 1998; Malmberg et al, 2000; Donahoe et al, 2007). Chronic heart failure affects one in five patients with diabetes, which is four-fold greater than the general population (Rubler et al, 1972). In addition, while improvements have been seen in recent decades in mortality rates in people with diabetes, the progress has been limited to the male population (Gregg et al, 2007).

The background to this risk for the development of cardiovascular complications is multifactorial and our understanding of the nature of atherosclerotic disease has progressed considerably. The concept that atherosclerosis is a gradual process, leading to narrowing of the arteries until such a point that a thrombus forms and occludes a vessel, is naive. The concept was originally questioned by pathologists who showed that most myocardial infarctions are caused by low-grade stenosis (Falk et al, 1995). The current approach is to define atherosclerotic plaques as either: stable, which can lead to high grade obstruction; or unstable, which are vulnerable to rupture and show a high incidence of thrombi (Davies, 1996).

The initial phase of the development of atherosclerosis is endothelial dysfunction caused by hyperglycaemia with or without hypertension and dyslipidaemia and the adverse effect of adipose tissue-derived inflammatory cytokines. These include tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). The effect of this is to produce adhesion molecules, inflammatory mediators and cytokines that stimulate the involvement of inflammatory cells such as monocytes, which then enter the vessel wall and further stimulate the inflammatory response by interacting with oxidised low-density lipoproteins (LDLs). In addition to this, there is a reduction in the release of nitric oxide (NO), leading to vessel

---

Citation: Kirby M (2013) Managing dyslipidaemia in the context of diabetes. *Diabetes & Primary Care* **15**: 141–8

Learning objectives

After reading this article the participant should be able to:

1. Outline the underlying process in the development of atherosclerosis and its contribution to major adverse cardiovascular events.

2. Define the relationship between lipid levels and cardiovascular risk in people with diabetes.

3. Describe the merits of the various options for lipid management in people with diabetes.

Key words

– Cardiovascular risk
– Cholesterol
– Dyslipidaemia

Author

Mike Kirby is Visiting Professor, Centre for Research in Primary & Community Care, University of Hertfordshire.

Page points

1. Plaques in people with diabetes are more likely to rupture, with consequent thromboembolic events, because of the inflammatory process within.

2. In addition to the effect on the arterial wall, there is a subset of people with diabetes who acquire diabetic cardiomyopathy during the course of this disease.

3. In diabetes, LDL cholesterol may not be significantly elevated compared with matched individuals without the disease, but is a smaller more dense and atherosclerotic particle.

constriction (Xu and Zou, 2009). Subsequently, the monocytes differentiate into macrophages and foam cells, which further stimulate the release of inflammatory mediators (Hansson, 2005). What can be seen at this stage is a fatty streak. The platelet hyperactivity that is present in diabetes probably contributes to the further development of lesions at this stage (Ross, 1999). Eventually, more complicated lesions occur and the core of the plaque becomes necrotic. This necrotic core is protected by a fibrous cap, and it is those lesions which have a thin and vulnerable fibrous cap that are likely to become unstable plaques (Hansson et al, 1988).

Plaques in people with diabetes are more likely to rupture, with consequent thromboembolic events, because of the inflammatory process within (Moreno et al, 2000). Recent techniques using intra-vascular ultrasound with virtual histology (IVUS-VH) have advanced our knowledge of plaque morphology (Lindsey et al, 2009).

In addition to the effect on the arterial wall, there is a subset of people with diabetes who acquire diabetic cardiomyopathy during the course of this disease. The nature of this process in not clearly defined, but there are functional and structural changes in the cardiac muscle that cause cardiac enlargement, increased stiffness and impaired diastolic function, which eventually leads to heart failure (Devereux et al, 2000). Heart failure is more common in the presence of poor glucose control, suggesting that hyperglycaemia may be an important contributor (Lind et al, 2011).

Clearly, good blood glucose control (i.e. reducing hyperglycaemia and avoiding hypoglycaemia in the process), particularly in the early stages of the disease, good blood pressure control throughout, and attention to dyslipidaemia is critically important in people with diabetes to prevent this atherosclerotic process (Colhoun et al, 2004; Holman et al, 2008).

Lipid levels and cardiovascular risk

In diabetes, LDL cholesterol may not be significantly elevated compared with matched

individuals without the disease, but is a smaller more dense and atherosclerotic particle (Mazzone et al, 2008).

The well-established treatment approach is to focus on the use of LDL cholesterol-lowering drugs such as statins. Statin therapy reduces cardiovascular events by 25–50% (Collins et al, 2003; Colhoun et al, 2004); however, there still appears to be an excess residual cardiovascular risk among statin-treated people with diabetes compared with those without the disease (Costa et al, 2006). This residual risk may result from lipoprotein abnormalities that occur in diabetes and which are not adequately addressed by statin therapy (Mazzone et al, 2008).

Dyslipidaemia in type 2 diabetes is characterised by increased concentrations of triglyceride-rich lipoproteins, decreased concentrations of high-density lipoprotein (HDL) cholesterol and abnormalities in the composition of triglyceride-rich HDL and LDL lipoprotein particles (Garvey et al, 2003; Deeg et al, 2007). HDL is a very complex lipoprotein particle and changes in its composition may affect its atherosclerotic properties (Mazzone, 2007). The failure of cholesterol ester transfer protein inhibition with torcetrapib to protect against cardiovascular events suggests that HDL particle composition may be a more

---

Box 1. High-density lipoprotein cholesterol functionality: relevance to athero- and vasculoprotection (Chapman, 2011).

- Regulation of glucose metabolism
- Cholesterol homeostasis and cellular cholesterol efflux
- Endothelial repair
- Anti-inflammatory activity
- Anti-oxidative activity
- Anti-apoptotic activity
- Anti-thrombotic activity
- Anti-protease activity
- Vasodilatory activity
- Anti-infectious activity

important consideration than HDL cholesterol level in the reduction of cardiovascular risk (Barter et al, 2007). *Box 1* examines the relevance of HDL cholesterol functionality to athero- and vasculoprotection.

The case for non-HDL cholesterol

It is likely that combined dyslipidaemia may confer a higher magnitude of risk than elevated LDL cholesterol alone (Assman and Schulte, 1992). Triglycerides appear to be an independent risk factor (Austin et al, 1998), although they may be a marker of low HDL cholesterol. Non-HDL cholesterol may be defined as the difference between total and HDL cholesterol and thus represents cholesterol carried on all the potentially pro-atherogenic particles (Hsai, 2003; see *Figure 1*). The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP) recommended non-HDL cholesterol as a secondary target in lipid lowering, after gaining adequate control of LDL cholesterol, if the triglycerides were elevated (≥200 mg/dL [2.3 mmol/L]; Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, 2001). By measuring total cholesterol and HDL cholesterol, and calculating non-HDL cholesterol, we can avoid the potential limitations of triglycerides as a marker of coronary heart disease (CHD) risk and instead measure something that directly reflects the cholesterol content of all the particles that


Figure 1. Components of non-high-density lipoprotein (non-HDL) cholesterol (redrawn with kind permission of the author from Virani, 2011).

may be pro-atherogenic. Another advantage of non-HDL cholesterol measurement is that it does not need to be done in the fasting state. Non-HDL cholesterol may be, therefore, a readily obtainable, inexpensive and convenient measure of CHD risk that may be superior to LDL cholesterol in many respects (Hsai, 2003).

A study by Lu et al (2003) highlighted the predictive value of non-HDL cholesterol for CHD and its potential role in the management of diabetic dyslipidaemia. It could therefore be considered a secondary target after achieving the total and LDL cholesterol targets as recommended by NICE: 4 and 2 mmol/L, respectively (NICE, 2009).

Table 1. Hazard ratios for major cardiovascular events by LDL and non-HDL cholesterol categories (Boekholdt et al, 2012).

LDL cholesterol level	Non-HDL cholesterol level	Hazard ratio	95% confidence interval
Not meeting target (2.6 mmol/L or higher)	Not meeting target (3.4 mmol/L or higher)	1.21	1.13–1.29
Not meeting target (2.6 mmol/L or higher)	**Meeting target** (under 3.4 mmol/L)	1.02	0.92–1.12
Meeting target (under 2.6 mmol/L)	Not meeting target (3.4 mmol/L or higher)	1.32	1.17–1.50
Meeting target (under 2.6 mmol/L)	**Meeting target** (under 3.4 mmol/L)	1.00*	

*Reference.

HDL=high-density lipoprotein; LDL=low-density lipoprotein.

A recent meta-analysis of individual patient data from randomised controlled statin trials, in which conventional lipids and apolipoproteins were determined in all study participants at baseline and 1-year follow-up, has been published in *JAMA*. The researchers used data from eight randomised trials in which nearly 40 000 patients received statins. One standard deviation increases from baseline levels of LDL, apolipoprotein B (apoB) and non-HDL at 1 year were all associated with increased risks of cardiovascular events but the differences between LDL and non-HDL were significant. Patients reaching the non-HDL target of under 130 mg/dL (3.4 mmol/L) but not the LDL target of under 100 mg/dL (2.6 mmol/L) were – assessed relative to patients achieving both targets – at lower excess risk than those reaching the LDL target but not the non-HDL target (Boekholdt et al, 2012; see *Table 1*).

Virani (2011), in the *Texas Heart Institute Journal*, has reviewed non-HDL cholesterol as a metric of good quality of care. Non-HDL cholesterol has been shown to be a better marker of risk in both primary and secondary prevention studies. In a recent analysis of data combined from 68 studies, non-HDL cholesterol was the best predictor among all cholesterol measures both for coronary artery events and for strokes (Emerging Risk Factors Collaboration, 2009). In the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) trial, elevated non-HDL cholesterol and apoB levels were the best predictors after acute coronary syndrome of adverse cardiovascular outcomes in patients on lipid-lowering therapy (Kastelein et al, 2008).

Elevated levels of non-HDL cholesterol, in combination with normal levels of LDL cholesterol, identify a subset of patients with elevated levels of LDL particle number, elevated apoB concentrations and LDL of small, dense morphology (Ballantyne et al, 2001). The increase in the incidence of metabolic syndrome probably reduces the accuracy of risk prediction for vascular events when LDL cholesterol is used for that purpose, whereas non-HDL cholesterol has been shown to retain predictive capability in this patient population (Sattar et al, 2004).

Lipid management

Elevated levels of non-HDL cholesterol are manageable with available lipid-lowering agents combined with intensive lifestyle modification. All of the currently available lipid-lowering agents, including statins, fibrates, niacins, fish oil products and intestinally active agents such as ezetimibe, decrease non-HDL cholesterol levels.

As noted earlier, NICE guidelines provide treatment goals of a total cholesterol level <4 mmol/L and an LDL cholesterol level <2 mmol/L (NICE, 2009).

In line with the NICE-recommended "audit level" for total cholesterol of 5 mmol/L (based on the observation that more than half of patients will not achieve a total cholesterol level <4 mmol/L or an LDL cholesterol level <2 mmol/L; NICE, 2008), the total cholesterol Quality and Outcomes Framework indicator for people with diabetes is as follows (NHS Commissioning Board et al, 2013):

"DM004. The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/l or less."

The US National Cholesterol Education Program Guidelines go one step further than NICE by recommending a target LDL cholesterol of <1.8 mmol/L in people with diabetes and established cardiovascular disease (Grundy et al, 2004). The American approach to hypertriglyceridaemia (defined as a triglyceride level of >2.2 mmol/L), which is present in many people with diabetes, is to target LDL cholesterol first and then use non-HDL cholesterol as a secondary target for treatment, with a goal 0.8 mmol/L higher than the LDL goal (Brunzell et al, 2008).

Contrary to the NICE guidelines, which recommend a fibrate when triglycerides are raised (NICE, 2009), the approach of many authorities in this situation is to use a non-HDL goal (0.8 mmol/L above the LDL goal) and intensify statin therapy, and if necessary add ezetimibe. Outcome data are now available for ezetimibe in combination

with statin therapy from SHARP (the Study of Heart and Renal Protection), confirming the benefit of lipid lowering in chronic renal disease (Baigent et al, 2011). The approach to very high triglycerides (>11 mmol/L) should also include a low-total-fat diet, a fibrate, and omega-3 fish oils (Hartweg et al, 2007; McEwan et al, 2010).

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial failed to demonstrate a benefit of adding fenofibrate to a statin compared with statin therapy alone in people with diabetes (ACCORD Study Group et al, 2010). There was a trend towards a reduction in adverse cardiovascular events in a predefined subgroup of patients with triglycerides ≥204 mg/dL (2.3 mmol/L) and an HDL cholesterol ≤34 mg/dL (0.8 mmol/L; P=0.057 for interaction).

Scott et al (2009) explored whether cardiovascular risk and the effects of fenofibrate differed in individuals with and without the metabolic syndrome and according to various features of the metabolic syndrome defined by the NCEP ATP III among people with type 2 diabetes in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study. The findings were that more than 80% of FIELD participants met the ATP III criteria for metabolic syndrome. Each ATP III feature of the metabolic syndrome, apart from increased waist circumference, increased the absolute risk of cardiovascular events over 5 years by at least 3%. Those with marked dyslipidaemia (elevated triglycerides [≥2.3 mmol/L] and low HDL cholesterol) were at the highest risk of cardiovascular disease (17.8% over 5 years). Fenofibrate significantly reduced cardiovascular events in those with low HDL cholesterol or hypertension. The largest effect of fenofibrate in reducing cardiovascular risk was observed among individuals with marked dyslipidaemia, in whom a 27% relative risk reduction (95% confidence interval, 9–42%, P=0.005; number needed to treat, 23) was observed. Subjects with no prior cardiovascular disease had greater risk reductions than the group as a whole. The authors concluded that metabolic syndrome

components identify higher cardiovascular risk in individuals with type 2 diabetes, and so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridaemia (Scott et al, 2009).

Recent data on niacin have been less encouraging. An outcomes trial comparing statin alone against statin plus niacin enrolled patients with established cardiovascular disease and atherogenic dyslipidaemia (LDL cholesterol ≤160 mg/dL (4.1 mmol/L) and HDL cholesterol <40 mg/dL (1.0 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women (ClinicalTrials.gov, 2011). The trial was halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population (National Institutes of Health, 2011).

HPS2-THRIVE (the Heart Protection Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events; http://www.thrivestudy.org/ [accessed 15.05.13]) involved over 25 000 men and women aged at least 50 years with a history of heart attack, stroke or peripheral arterial disease. All study participants were given simvastatin and, if necessary, ezetimibe to ensure good control of LDL cholesterol. In addition, they were randomly allocated to receive extended-release niacin/laropiprant (Tredaptive™) or matching placebo tablets daily for approximately 4 years. The primary objective of the study was to investigate whether fewer participants given extended-release niacin/laropiprant had heart attacks, strokes or revascularisation procedures or died from coronary heart disease than those in the placebo arm. Professor Jane Armitage, HPS2-THRIVE Chief Investigator, said:

"The preliminary HPS2-THRIVE results show that, when added to an effective statin-based treatment, the combination of extended-release niacin and laropiprant does not produce clinically meaningful reductions in the rate of major vascular events (such as heart attacks and strokes)."

Page points

1. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridaemia.

2. An outcomes trial comparing statin alone against statin plus niacin enrolled patients with established cardiovascular disease and atherogenic dyslipidaemia but was halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population.

Box 2. Case example one.

Narrative

Mr B is a 62-year-old man who has had type 2 diabetes for 6 years. He weighs 98 kg with a BMI of 30 kg/m^2 and his HbA$_{1c}$ level is 60 mmol/mol (7.6%). His estimated glomerular filtration rate is 58 mL/min/1.73 m^2 and his blood pressure is 146/88 mmHg. He takes metformin 0.5 g twice daily and ramipril 5 mg daily and follows a healthy lifestyle programme diligently.

He had been on atorvastatin 40 mg but reported muscle pain and cramps in his legs. These disappeared when the statin was stopped but his lipid profile was unsatisfactory, with a cholesterol level of 5.4 mmol/L, high-density lipoprotein (HDL) cholesterol level of 0.9 mmol/L, triglyceride level of 2.7 mmol/L and low-density lipoprotein (LDL) cholesterol of 3.3 mmol/L.

His calculated 10-year risk of coronary heart disease (CHD) was 40.6%, fatal CHD 26.4%, stroke 15.2% and fatal stroke 2.5%.

Discussion

Mr B was subsequently started on pravastatin 40 mg. His muscle pains were no longer a problem but his targets (total cholesterol level of 4 mmol/L and LDL cholesterol level of 2 mmol/L) remained elusive until ezetimibe 10 mg was additionally prescribed. Amlodipine 5 mg was also added to his regimen to achieve a target blood pressure of less than 130/80 mmHg, and metformin was titrated up to 2 g.

MSD has advised clinicians to stop prescribing Tredaptive™ and to review patients on the drug in a timely fashion (Merck, 2013).

Case examples relating to managing dyslipidaemia in the context of diabetes are presented in *Box 2* and *Box 3*.

Box 3. Case example two.

Narrative

Mrs D, a teacher aged 48 years, attends for an NHS health check. She is overweight (96 kg), with central obesity and a waist measurement of 90 cm. Her blood pressure measures 150/88 mmHg. A random blood glucose test is performed in addition to tests for total cholesterol, high-density lipoprotein (HDL) cholesterol and estimated glomerular filtration rate.

Her cholesterol level was 5.8 mmol/L with HDL cholesterol at 0.95 mmol/L. Her glucose level was 7.1 mmol/L and her renal function was normal.

A subsequent glucose tolerance test confirmed type 2 diabetes with a fasting glucose level of 7.2 mmol/L and a 2-hour glucose level of 12 mmol/L. LDL cholesterol level was 3.57 mmol/L and triglycerides were 2.8 mmol/L. Her HbA$_{1c}$ level was 8.2% (66 mmol/mol). No end organ damage was identified and there was no microalbuminuria.

Discussion

Mrs D was provided with lifestyle advice and started on simvastatin 40 mg and an angiotensin-converting enzyme inhibitor as her blood pressure remained high. Metformin will be introduced if the HbA$_{1c}$ level fails to fall below 53 mmol/mol (7.0%) with the diet and exercise diabetes regimen.

Concluding remarks

The American Diabetes Association (2009) guidelines suggest that if lipid targets are not achieved on maximally tolerated doses of statins, combining a statin with other lipid-lowering therapy may be considered to achieve lipid targets. This recommendation is based on expert consensus. Randomised trials demonstrating reductions in adverse cardiovascular end points (myocardial infarction, stroke and death) are currently lacking.

We therefore must be pragmatic and attempt to deal with the residual risk in people with diabetes after appropriate LDL cholesterol lowering using non-HDL cholesterol as a secondary target. ■

ACCORD Study Group, Ginseberg HN, Elam MB et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* **362**: 1563–73

American Diabetes Association (2009) Standards of medical care in diabetes—2009. *Diabetes Care* **32**(Suppl 1): S13–S61

Assman G, Schulte H (1992) Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). *Am J Cardiol* **70**: 733–7

Austin MA, Hokanson JE, Edwards KL (1998) Hypertriglyceridaemia as a cardiovascular risk factor. *Am J Cardiol* **81**(Suppl 4A): 7B–12B

Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* **377**: 2181–92

Ballantyne CM, Andrews TC, Hsai JA et al (2001) Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. *Am J Cardiol* **88**: 265–9

Barter PJ, Caulfied M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med* **357**: 2109–22

Boekholdt SM, Arsenault BJ, Mora S et al (2012). Association of LDL cholesterol, non-HDL cholesterol and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA* **307**: 1302–9

Brunzell JD, Davidson M, Furberg CD et al (2008) Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care* **31**: 811–22

Chapman MJ, Ginsberg HN, Amarenco P et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J* **32**: 1345–61

ClinicalTrials.gov (2011) *Niacin Plus Statin to Prevent Vascular Events*. National Institutes of Health, Bethesda, MD, USA. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00120289 (accessed 15.05.13)

Colhoun HM, Betteridge DJ, Durrington PN et al (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet* **364**: 685–96

Collins R, Armitage J, Parish S et al (2003) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* **361**: 2005–16

Costa J, Borges M, David C, Vaz CA (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. *BMJ* **332**: 1115–24

Davies MJ (1996) Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. *Circulation* **94**: 2013–2020

Deeg MA, Buse JB, Goldberg RB et al (2007) Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidaemia. *Diabetes Care* **30**: 2458–64

Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function: the strong heart study. *Circulation* **101**: 2271–6

Donahoe SM, Stewart GC, McCabe CH et al (2007) Diabetes and mortality following acute coronary syndromes. *JAMA* **298**: 765–75

Emerging Risk Factors Collaboration (2009) Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* **302**: 1993–2000

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* **285**: 2486–96

Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. *Circulation* **92**: 657–71

Garvey WT, Kwon S, Zheng D et al (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. *Diabetes* **52**: 453–62

Gregg EW, Gu Q, Cheng YJ et al (2007) Mortality trends in men and women with diabetes, 1971 to 2000. *Ann Intern Med* **147**: 149–55

Grundy SM, Cleean JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* **110**: 227–39

Haffner SM, Lehto S, Ronnemaa T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic patients with and without prior myocardial infarction. *N Engl J Med* **339**: 229–34

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* **352**: 1685–95

Hansson GK, Jonasson L, Lojsthed B et al (1988) Localization of T lymphocytes and macrophages in fibrous and complicated human atheroslcerotic plaques. *Atherosclerosis* **72**: 135–41

Hartweg J, Farmer AJ, Perera R et al (2007) Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. *Diabetologia* **50**: 1593–602

Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359(15): 1577–89

Hsai S (2003) Non-HDL cholesterol: Into the spotlight. *Diabetes Care* **26**: 240–2

Kastelein JJ, van der steeg WA, Holme I et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation* **117**: 3002–9

Lind M, Bounias I, Olsson M et al (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: An observational study. *Lancet* **378**: 140–6

Lindsey JB, House JA, Kennedy KF, Marso SP (2009) Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascular ultrasound with virtual histology. *Circ Cardiovasc Interv* **2**: 543–8

Lu W, Resnick HE, Jablonski KA et al (2003) Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. *Diabetes Care* **26**: 16–23

Malmberg K, Yusuf S, Gerstein HC et al (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (organization to assess strategies for ischaemic syndromes) registry. *Circulation* **102**: 1014–9

Mazzone T (2007) HDL cholesterol and atherosclerosis. *Lancet* **370**: 107–8

Mazzone T, Chait A, Plutzky J (2008) Addressing cardiovascular disease risk in diabetes: insights from mechanistic studies. *Lancet* **371**: 180–9

McEwan B, Morel-Kopp MC, Tofler G, Ward C (2010) Effect of omega-3 fish oil on cardiovascular risk in diabetes. *Diabetes Educ* **36**: 565–84

Merck (2013) *Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)*. Merck, Whitehouse Station, NJ, USA. Available at: http://bit.ly/UQS54R (accessed 15.05.13)

Moreno PR, Murcia AM, Palacios IF (2000) Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. *Circulation* **102**: 2180–4

National Institutes of Health (2011) *NIH stops clinical trial on combination cholesterol treatment*. NIH, Bethesda, MD, USA. Available at: http://1.usa.gov/kSfScN (accessed 15.05.13)

NHS Commissioning Board, British Medical Association, NHS Employers (2013) *Quality and Outcomes Framework guidance for GMS contract 2013/14*. NHS, London. Available at: http://bit.ly/Xk1mq1 (accessed 15.05.13)

NICE (2008) *Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease*. Available at: http://www.nice.org.uk/cg67 (accessed 15.05.13)

NICE (2009) *Type 2 Diabetes – newer agents (partial update of CG66)*. Available at: http://www.nice.org.uk/cg87 (accessed 15.05.13)

Ross R (1999) Atherosclerosis – an inflammatory disease. *N Engl J Med* **340**: 115–26

Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am J Cardiol* **30**: 595–602

Sattar N, Williams K, Sniderman AD et al (2004) Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. *Circulation* **110**: 2687–93

Scott R, O'Brien R, Fulcher G et al (2009) Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care* **32**: 493–8

Virani S (2011) Non-HDL cholesterol as a metric of good quality of care. *Tex Heart Inst J* **38**: 160–2

Xu J, Zou MH (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. *Circulation* **120**: 1266–86

"We must be pragmatic and attempt to deal with the residual risk in people with diabetes after appropriate low-density lipoprotein cholesterol lowering using non-high-density lipoprotein cholesterol as a secondary target."

Online CPD activity

Visit www.diabetesonthenet.com/cpd to record your answers and gain a certificate of participation

Participants should read the preceding article before answering the multiple choice questions below. There is ONE correct answer to each question. After submitting your answers online, you will be immediately notified of your score. A pass mark of 70% is required to obtain a certificate of successful participation; however, it is possible to take the test a maximum of three times. A short explanation of the correct answer is provided. Before accessing your certificate, you will be given the opportunity to evaluate the activity and reflect on the module, stating how you will use what you have learnt in practice. The new CPD centre keeps a record of your CPD activities and provides the option to add items to an action plan, which will help you to collate evidence for your annual appraisal.

1. Which of the following statements BEST explains current understanding of how atherosclerotic disease causes myocardial infarction? Select ONE option only.

    A. Atherosclerosis gradually leads to narrowing of coronary arteries
    B. Atherosclerosis causes an increased systemic thrombotic tendency
    C. Thrombus forms once coronary arteries become too narrow
    D. Unstable atherosclerotic plaques rupture

2. Which ONE of the following inflammatory cytokines has been clearly implicated in the INITIAL development of atherosclerosis? Select ONE option only.

    A. Insulin
    B. Interferon-gamma (IFN-gamma)
    C. Interleukin-2 (IL-2)
    D. Tumour necrosis factor-alpha (TNF-alpha)

3. Arterial constriction occurs in response to REDUCED release of which one of the following? Select ONE option only.

    A. Carbon dioxide
    B. Nitric oxide
    C. Nitrogen
    D. Oxygen

4. Which of the following haematological factors is MOST LIKELY associated with the progression of atherosclerosis in people with diabetes? Select ONE option only.

    A. Platelet hyperactivity
    B. Polycythaemia
    C. Thrombocythaemia
    D. All of the above
    E. None of the above

5. The presence of which of the following, if any, BEST explains why some people with diabetes develop diabetic cardiomyopathy? Select ONE option only.

    A. Hyperglycaemia
    B. Hyperlipidaemia
    C. Hypertension
    D. Hyperviscosity
    E. None of the above

6. According to research data, statin therapy in people with diabetes reduces the relative risk of cardiovascular events by which approximate percentage? Select ONE option only.

    A. 5–10
    B. 15–30
    C. 25–50
    D. 30–60
    E. 50–70

7. Which of the following activities is NOT a component of HDL's vasculo-protective functionality? Select ONE option only.

    A. Anti-constrictive
    B. Anti-infectious
    C. Anti-inflammatory
    D. Anti-protease
    E. Anti-thrombotic

8. According to NICE guidelines, which is the recommended TARGET for people with diabetes and dyslipidaemia? Select ONE option only.

	Total cholesterol (mmol/L)	HDL cholesterol (mmol/L)
A.	5	3
B.	5	2
C.	4	3
D.	4	2
E.	3	3
F.	3	2

9. "Non-HDL cholesterol" is BEST defined as the difference between which two of the following? Select ONE option only.

    A. HDL cholesterol and LDL cholesterol
    B. HDL cholesterol and triglycerides
    C. Total cholesterol and HDL cholesterol
    D. Total cholesterol and triglycerides

10. A 57-year-old man with type 2 diabetes has persistent hypertriglyceridaemia despite taking daily simvastatin 40 mg and addressing lifestyle factors.

    Which of the following is the LEAST effective management option? Select ONE option only.

    A. Add ezetimibe
    B. Add fenofibrate
    C. Increase simvastatin
    D. Switch to atorvastatin
    E. Switch to niacin